tiprankstipranks
Trending News
More News >
Vimian Group AB (SE:VIMIAN)
:VIMIAN
Advertisement

Vimian Group AB (VIMIAN) AI Stock Analysis

Compare
1 Followers

Top Page

SE:VIMIAN

Vimian Group AB

(Frankfurt:VIMIAN)

Select Model
Select Model
Select Model
Neutral 57 (OpenAI - 4o)
Rating:57Neutral
Price Target:
kr34.00
▲(12.21% Upside)
Vimian Group AB's overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators and a high P/E ratio suggesting overvaluation. The lack of earnings call data and corporate events means these factors do not impact the score.
Positive Factors
Negative Factors

Vimian Group AB (VIMIAN) vs. iShares MSCI Sweden ETF (EWD)

Vimian Group AB Business Overview & Revenue Model

Company DescriptionVimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyVimian Group AB generates revenue through a diversified portfolio of products and services in the animal health industry. The company earns money primarily by selling pharmaceuticals, diagnostic equipment, and medical devices to veterinary clinics and animal hospitals. Additionally, Vimian offers specialized veterinary services that contribute to its income. The company's revenue streams are further supported by strategic partnerships with other leading firms in the veterinary sector, which enhance its product offerings and market reach. Key factors such as the increasing demand for advanced animal healthcare solutions and a growing pet population contribute significantly to Vimian's earnings.

Vimian Group AB Financial Statement Overview

Summary
Vimian Group AB exhibits solid financial performance with consistent revenue growth and strong cash flow generation. Profitability margins are stable, but there is room for improvement in net profit margins. The balance sheet reflects a prudent leverage strategy, though returns on equity could be enhanced.
Income Statement
72
Positive
Vimian Group AB shows a consistent revenue growth trajectory, with a TTM revenue growth rate of 3.4%. Gross profit margins remain strong at approximately 68.7%, indicating efficient cost management. However, net profit margins are relatively low at 5.6%, suggesting room for improvement in profitability. EBIT and EBITDA margins are stable, reflecting operational efficiency.
Balance Sheet
65
Positive
The company's debt-to-equity ratio is moderate at 0.43, indicating a balanced approach to leveraging. Return on equity is low at 3.3%, suggesting limited returns for shareholders. The equity ratio stands at 60.1%, showing a solid equity base relative to total assets, which enhances financial stability.
Cash Flow
78
Positive
Vimian Group AB demonstrates strong cash flow management with a significant free cash flow growth rate of 29.3% in the TTM period. The operating cash flow to net income ratio is healthy at 0.85, indicating efficient cash generation relative to net income. The free cash flow to net income ratio is robust at 0.84, reflecting strong cash conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue404.35M374.80M331.73M281.31M173.35M137.75M
Gross Profit277.82M258.30M229.43M193.99M122.85M95.52M
EBITDA87.72M82.80M69.19M66.32M40.98M65.16M
Net Income22.67M18.50M9.84M-7.20M6.59M52.79M
Balance Sheet
Total Assets1.14B1.11B973.68M923.56M640.72M456.29M
Cash, Cash Equivalents and Short-Term Investments67.50M64.80M37.50M42.19M55.11M29.66M
Total Debt294.00M233.60M313.80M220.96M180.37M85.91M
Total Liabilities444.80M403.30M446.97M442.06M282.08M182.05M
Stockholders Equity682.90M699.90M526.37M481.81M357.41M224.02M
Cash Flow
Free Cash Flow67.15M43.90M-43.48M15.01M4.52M-793.00K
Operating Cash Flow80.38M58.10M-28.58M25.31M16.01M4.80M
Investing Cash Flow-148.90M-76.00M-77.68M-188.53M-115.00M-105.24M
Financing Cash Flow97.10M44.80M100.55M150.23M123.94M118.57M

Vimian Group AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price30.30
Price Trends
50DMA
33.42
Negative
100DMA
37.03
Negative
200DMA
38.59
Negative
Market Momentum
MACD
-0.73
Negative
RSI
39.46
Neutral
STOCH
22.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Negative. The current price of 30.3 is below the 20-day moving average (MA) of 31.17, below the 50-day MA of 33.42, and below the 200-day MA of 38.59, indicating a bearish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 39.46 is Neutral, neither overbought nor oversold. The STOCH value of 22.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
20.36B137.5518.57%44.52%-49.29%
60
Neutral
23.30B67.876.40%0.39%4.56%185.59%
57
Neutral
€15.87B62.473.34%15.07%117.65%
57
Neutral
17.87B39.733.43%0.83%0.14%0.00%
53
Neutral
19.18B71.123.02%4.78%-1.54%-75.84%
35
Underperform
24.05M-0.270.00%-67.76%95.76%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:VIMIAN
Vimian Group AB
30.30
-12.75
-29.62%
GB:0O5H
Elekta AB
50.42
-12.73
-20.16%
GB:0YAY
Vitrolife AB
131.60
-108.45
-45.18%
ADDLF
AddLife AB
20.33
4.72
30.24%
NLTBF
Nolato AB
6.40
1.28
25.00%
DE:61MA
MedCap AB
54.90
11.80
27.38%

Vimian Group AB Corporate Events

Vimian Group AB Increases Shares and Voting Power
Jul 31, 2025

Vimian Group AB announced an increase in the number of shares and votes due to the exercise of warrants and conversion of class C shares into ordinary shares. This change reflects the company’s strategic financial adjustments and may impact its market positioning by enhancing shareholder value and voting power distribution.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group CEO Resigns; Interim Leadership Appointed
Jul 17, 2025

Vimian Group AB announced the immediate resignation of CEO Patrik Eriksson, with CFO Carl-Johan Zetterberg Boudrie stepping in as interim CEO. The company is initiating a search for a new CEO to drive its strategic focus on profitable growth and leveraging its global scale. The changes are part of Vimian’s efforts to strengthen its leadership and continue its growth trajectory in the animal health industry.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group to Release Q2 2025 Interim Report with Investor Audiocast
Jul 7, 2025

Vimian Group AB has announced the release of its Interim Report for the second quarter of 2025, scheduled for publication on July 18. The company will host an audiocast for investors, analysts, and media, where CEO Patrik Eriksson and CFO Carl-Johan Zetterberg Boudrie will present and discuss the report. This event underscores Vimian’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Expands Share Base with Warrant Exercise
Jun 30, 2025

Vimian Group AB announced an increase in its number of shares and votes following the exercise of warrants from a program approved in 2022. This change reflects the addition of 2,724,260 ordinary shares, bringing the total to 526,615,332 shares, with a corresponding increase in voting rights. This development may enhance Vimian’s market position by potentially increasing its capital base and shareholder engagement.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Launches Employee Incentive Program Subscription
Jun 17, 2025

Vimian Group AB has initiated the subscription period for its 2022-2025 incentive program, allowing employees to subscribe to shares through a warrant program. To support this, some warrant holders have sold shares, and Vimian’s major shareholder, Fidelio Vet Holding AB, facilitated the process by lending shares to the investment bank handling the transaction. This strategic move aims to enhance liquidity and ensure a smooth subscription process for both local and foreign warrant holders, maintaining Fidelio’s shareholding position.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Expands Dental Portfolio with AllAccem Acquisition
Jun 13, 2025

Vimian Group AB has announced the acquisition of AllAccem Inc., a leading provider of veterinary dental sealant products in the US, as part of its strategy to enhance its veterinary dental offerings. This acquisition, which will integrate AllAccem into Vimian’s MedTech segment, is expected to bolster Vimian’s position in the fast-growing niche of animal dental health, leveraging AllAccem’s high-margin products and strong market presence to improve global animal dental care.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Adopts New Incentive Programs and Remuneration Guidelines
Jun 11, 2025

Vimian Group AB held an Extraordinary General Meeting on June 11, 2025, where shareholders approved several key resolutions. These included adopting new Articles of Association to introduce reclassifiable and redeemable share classes for the company’s incentive program, implementing a long-term performance-based share program for employees and consultants, and updating remuneration guidelines to allow for incentive programs to be adopted by both Annual and Extraordinary General Meetings. These changes are expected to enhance Vimian’s operational flexibility and align with local laws and practices, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Successfully Issues EUR 150 Million in Bonds
May 13, 2025

Vimian Group AB has successfully issued EUR 150 million in senior unsecured bonds, significantly oversubscribed, with plans to list them on Nasdaq Stockholm. This move reflects strong investor confidence and is expected to enhance Vimian’s financial flexibility, supporting its growth in the animal health sector.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Plans EUR 125 Million Bond Issuance
May 9, 2025

Vimian Group AB is considering issuing a senior unsecured bond to raise EUR 125 million, with a potential framework of EUR 250 million, subject to market conditions. The proceeds will be used to refinance existing debt and support corporate activities, including acquisitions and investments, potentially impacting its financial strategy and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025